In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Investigators evaluated outcomes for patients with pediatric AML with and without etoposide during first-line induction treatment.
Identity disclosure to a family member or friend linked to increased risks for suicide intention, plan, attempt.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of cataplexy or excessive ...
The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for efficacy and safety in patients with relapsed/refractory follicular lymphoma in ...
Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.
HealthDay News — A rare case of rabies linked to an organ transplant has resulted in 2 deaths, federal health officials announced. The US Centers for Disease Control and Prevention (CDC) reported that ...
In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.
Omidubicel is a nicotinamide modified unrelated allogeneic hematopoietic progenitor cell therapy derived from cord blood.
Except for public health advocates (72% opposed), more than 60% of each speaker type supported approval. Patients and family members with drug experience had the highest support for approval (99%), 12 ...
At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.
If the products were acquired through the Novo Nordisk Patient Assistance Program, the product is genuine and not counterfeit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results